Rubicon Organics Inc
XTSX:ROMJ
Rubicon Organics Inc
XTSX:ROMJ
Price:
0.495
CAD
-2.94%
Market Closed
Market Cap:
CA$33.3m
Relative Value
The Relative Value of one
ROMJ
stock under the Base Case scenario is
0.805
CAD.
Compared to the current market price of 0.495 CAD,
Rubicon Organics Inc
is
Undervalued by 38%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ROMJ
Relative Value
Base Case
0.805
CAD
Undervaluation 38%
Multiples Across Competitors
ROMJ Competitors Multiples
Rubicon Organics Inc Competitors
Rubicon Organics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Rubicon Organics Inc
XTSX:ROMJ
|
34.3m CAD | 0.6 | 10.3 | 1.6 | 1.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867.4B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.4B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.1 | 19.5 | 11.5 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
220.3B GBP | 5 | 28.9 | 16 | 22.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF | 5.2 | 20.9 | 13 | 16.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.3B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD | 2.5 | 17 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
